Mitoxantrone Hydrochloride liposomal Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Mitoxantrone Hydrochloride liposomal Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Mitoxantrone Hydrochloride liposomal can convert its Small molecule drug, Liposomal Drug profile and Top II biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Mitoxantrone Hydrochloride liposomal (query alias: Mitoxantrone Hydrochloride liposomal) |
|---|---|
| Modality / target | Small molecule drug, Liposomal Drug; Top II; Top II inhibitors |
| Highest global status | Approved |
| Originator | CSPC Pharmaceutical Group Ltd. |
| Active developers | Shanghai JMT Biological Technology Co Ltd, CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd., CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. |
The MCP disease footprint includes Peripheral T-Cell Lymphoma, Acute Myeloid Leukemia, Nasopharyngeal Cancer, Recurrent. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600124493 | Phase 4 | Not yet recruiting | 30 | Objective Response Rate |
| NCT07525466 | Phase 1/2 | Recruiting | 25 | 6-month overall survival (OS) rate |
| NCT07389356 | Not Applicable | Not yet recruiting | 70 | Complete response rate (CRR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Response to HiDAC/mitoxantrone/venetoclax (HMV) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Not Applicable; n=16; evaluation: Positive. Reported fields: Adverse ELN 2022 risk = 50.0 %
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Phase 2; n=39; evaluation: not stated. Reported fields: Biochemical Response = 0 Participants ; -; -
SAFETY AND EFFICACY OF MITOXANTRONE LIPOSOME COMBINED CHEMOTHERAPY IN THE TREATMENT OF MIXED PHENOTYPE ACUTE LEUKEMIA
Not Applicable; n=16; evaluation: Positive. Reported fields: AE = The main adverse effects were hematological toxicities. The incidence of agranulocytosis was 100%, the median duration time was 9 days (ranging from 2 to 18 days). The incidences of grade 4, grade 3, and grade 2 thrombocytopenia were 85.3%, 8.8%, and 5.9%, respectively. Only 4 cases (11.8%) of grade 3 transaminase elevation were observed, and no other obvious organ toxicity was observed.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Mitoxantrone Hydrochloride liposomal addresses Peripheral T-Cell Lymphoma, Acute Myeloid Leukemia, Nasopharyngeal Cancer, Recurrent. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug, Liposomal Drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 203 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Top II records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-03 | Sam Chun Dang Pharm expands strategic partnership with Dr. Reddy's Laboratories through liposomal drug collaboration | Approved | Financial terms not disclosed |
| 2026-05-11 | 科兴制药与大光制药达成出海合作 携手拓展眼科产品海外市场 | Approved | Financial terms not disclosed |
| 2026-04-24 | 爱科瑞思携手K2 Therapeutics，共推ACR246全球临床开发 | Phase 1/2 | US$730.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
